Tremor: A newly described adverse event with long-term itraconazole therapy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 3, 2010, Pages 327-329

  Lestner, Jodi M ^a   Denning, David W ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Regional Mycology Laboratory   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMPHOTERICIN B; ATENOLOL; AZITHROMYCIN; DIGOXIN; ENALAPRIL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FUROSEMIDE; HUMAN INSULIN; ITRACONAZOLE; LANSOPRAZOLE; LATANOPROST; LORATADINE; MONTELUKAST; RISEDRONIC ACID; SALBUTAMOL; SIMVASTATIN; THEOPHYLLINE; TRIAMCINOLONE; VORICONAZOLE; WARFARIN; ZOLPIDEM;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; LUNG ASPERGILLOSIS; MALE; MYCOBACTERIOSIS; PRIORITY JOURNAL; TREMOR;

AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ITRACONAZOLE; LONG-TERM CARE; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, ATYPICAL; PULMONARY ASPERGILLOSIS; TREMOR;

EID: 77649159189     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.174706     Document Type: Article

References (14)

1. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001;61(Suppl 1):39-47.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
3. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
4. Tucker RM, Haq Y, Denning DW, et al. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.
5. Dismukes WE, Bradsher RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992;93:489-97.
6. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089-93.
7. Graybill JR, Stevens DA, Galgiani JN, et al. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med 1990;89:282-90.
8. Anouti A, Koller WC. Tremor disorders. Diagnosis and management. West J Med 1995;162:510-13.
9. Mott SH, Packer RJ, Vezina LG, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B. Ann Neurol 1995;37:810-14.
10. Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007;2:231-43.
11. Tucker RM, Arathoon EG, Stevens DA. Treatment of mycoses with itraconazole. Ann N Y Acad Sci 1988;544:451-70.
12. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(Suppl 1):67-87.
13. Eiden C, et al. Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41:755-63.
14. Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med J 1999;38:829-32.